Foamix Pharmaceuticals (FOMX) Given Daily Coverage Optimism Rating of 0.22

News articles about Foamix Pharmaceuticals (NASDAQ:FOMX) have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Foamix Pharmaceuticals earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned media headlines about the specialty pharmaceutical company an impact score of 45.5765783504908 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Shares of Foamix Pharmaceuticals (FOMX) traded up $0.12 during mid-day trading on Monday, hitting $6.70. The company’s stock had a trading volume of 132,500 shares, compared to its average volume of 130,367. Foamix Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $11.11. The stock has a market cap of $250.80, a PE ratio of -5.11 and a beta of 1.62.

Foamix Pharmaceuticals (NASDAQ:FOMX) last issued its earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.47) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.03). The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $0.90 million. Foamix Pharmaceuticals had a negative return on equity of 54.81% and a negative net margin of 1,439.32%. Foamix Pharmaceuticals’s quarterly revenue was down 64.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.19) earnings per share. equities analysts anticipate that Foamix Pharmaceuticals will post -1.35 earnings per share for the current fiscal year.

Several brokerages have issued reports on FOMX. Zacks Investment Research cut Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd. HC Wainwright set a $12.00 price target on Foamix Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, November 29th. Finally, Guggenheim reissued a “buy” rating and issued a $8.00 price target on shares of Foamix Pharmaceuticals in a report on Thursday, December 14th.

COPYRIGHT VIOLATION NOTICE: “Foamix Pharmaceuticals (FOMX) Given Daily Coverage Optimism Rating of 0.22” was first published by BBNS and is the property of of BBNS. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://baseballnewssource.com/markets/foamix-pharmaceuticals-fomx-receives-news-impact-rating-of-0-22/1818463.html.

About Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

Insider Buying and Selling by Quarter for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.